Navigation Links
Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL

The 42nd Annual Meeting of the European Association for the Study of the Liver

PRINCETON, N.J., April 03, 2007 /PRNewswire/ -- Pharmasset announced today that presentations of preclinical studies of Clevudine for the treatment of hepatitis B (HBV) and PSI-6130, the parent molecule of R7128, for the treatment of hepatitis C (HCV) will be made during the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) being held in Barcelona, Spain from April 11-15, 2007. The PSI-6130 studies were conducted through Pharmasset's HCV collaboration with Roche. Dr. Phillip Furman, Pharmasset's Vice President of Biological Sciences, will be presenting Pharmasset's posters beginning on Thursday, April 12, 2007 at 7:00pm (CEST). The complete abstracts can be viewed at http://www.easl.ch/liver-meeting.

Clevudine is Efficiently Phosphorylated to the Active Triphosphate form in Human Hepatocytes

    C. Niu 1, E. Murakami 1, M.J. Otto 1, P.A. Furman 1

    1 Pharmasset, Inc., Princeton, NJ, USA

    Study subject:  initial half-life of the clevudine triphosphate.

Inhibition of HCV Replication by PSI-6130: Characterization of Activity in the HCV Replicon System

W.R. Jiang 1, S. Ali 1, S. Le Pogam 1, C. Daniel 1, S. Chiu 1, T. Kretz 1, I. Najera 1, P. Furman 2, N. Cammack 1, J. Symons 1

1 Roche Palo Alto LLC, Palo Alto, CA, USA; 2 Pharmasset Inc., Princeton, NJ, USA

Study subject: inhibition of HCV replication using combinations of PSI- 6130 with other HCV inhibitors.

Inhibition of HCV Replication by PSI-6130: Mechanism of Biochemical Activation and Inhibition

P.A. Furman 1, E. Murakami 1, H. Bao 1, J. Symons 2, M.J. Otto 1

1 Pharmasset, Inc., Princeton, NJ, USA; 2 Roche Palo Alto LLC, Palo Alto, CA, USA

Study subject: investigation of the enzymes involved in the phospho
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... August 28, 2015 The report "Eubiotics Market by ... Poultry, Ruminant, and Aquaculture), & by Region ( North ... Asia-Pacific , and Rest of the World) - Global ... market for Eubiotics was valued at USD 4.62 Billion in ... 2020, at a CAGR of 7.4% from 2015 to 2020. ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... May 12, 2011 Polaris Group (Polaris) today announced ... its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during ... p.m. China Standard Time in Taipei, Taiwan. ... of ADI-PEG 20 in hepatocellular carcinoma (HCC) will be ...
... SANTA CLARA, Calif., May 12, 2011 Cell Biosciences, ... Inc. of Ottawa, Ontario for approximately U.S. $9 million ... market leader in Micro-Flow Imaging (MFI), an analytical technique ... Because of high interest in protein aggregation expressed by ...
Cached Medicine Technology:Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 2Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 3Cell Biosciences Acquires Brightwell Technologies 2
(Date:8/29/2015)... ... ... Rio Salado College President Chris Bustamante announced on Aug. 19 ... Initiatives and Information Services. O’Shea, who has served Rio Salado for the last two ... through innovative technologies and strategies. , “I am very proud to be able to ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... to insufficient scrotal support and protection against dribbled urine and sweat. "In order ... Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
(Date:8/28/2015)... ... 29, 2015 , ... Rio Salado College joined nine educational institutions ... part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded ... Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed to ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published ... maker Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. LaRocco ... tends to take several months, but the current process, having already gone on for ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2
... A HIV protease inhibitor Aptivus ( tipranavir ) , has ... // . The capsules are to be given in combination ... the second drug approved for patients with advanced HIV disease, ... options., ,The benefits of Aptivus in combination with ritonavir, ...
... on bipolar disorder conducted by the World Federation for ... feel that their quality of life suffers because of ... characterized by successive feelings of elation and depression. Also ... 5 of the global adult population. This is a ...
... may be reacting to varying degrees of energy loss during ... genetic predisposition. How our bodies react to exercise programs is ... exercising like the level of blood glucose in the body ... of scientists from Washington University School of Medicine, exercise can ...
... around now for almost 40 years for treatment skin ... maybe useful in treating cancer as it has been shown ... was reported by international team of scientists. Leslie Wilson, professor ... Barbara, The results are published in online edition of the ...
... time in India ,German Remedies, a part of the Zydus ... of chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia (CLL) is a ... which at present has no cure. The disease is unknown ... more common with increasing age. ,Fludarabine has emerged ...
... Researchers have found that teenage girls living in temperate countries ... in life if they took supplements of Vitamin D in ... is low. The sun is important for formation of the ... ,The vitamin supplement would help to strengthen bones for later ...
Cached Medicine News:Health News:Vitamin D Supplement in Teenage Girls essential in Winter months 2
... drainage set (EVD set) drains ... external ventricular drainage. It can ... a ventricular catheter or with ... from the Aesculap Spiegelberg ICP, ...
... The CODMAN EDS 3 CSF External Drainage ... 200 nurses and physicians. The clinicians who work ... distinguish the CODMAN EDS 3: ease-of-use in an ... SPLASHFREE valve, accurate hydrostatic leveling from a ...
Monitorr ICP external CSF drainage system with self-contained ICP setting....
Monitorr ICP external CSF drainage and monitoring system with patient line one way valve....
Medicine Products: